# Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

> **NCT04841512** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Xalud Therapeutics, Inc.**

## Conditions studied

- Osteoarthritis, Spine

## Interventions

- **BIOLOGICAL:** XT-150

## Key facts

- **NCT ID:** NCT04841512
- **Lead sponsor:** Xalud Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** COVID - Lack of recruitment
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04841512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04841512, "Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04841512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*